Neuphoria Therapeutics (NEUP) Other Non Operating Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Other Non Operating Income of -$291522.0 for Q1 2026, down 268.56% year-over-year from $172946.0 in Q1 2025, and down 114.89% quarter-over-quarter from -$135659.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Other Non Operating Income (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Other Non Operating Income for 4 consecutive years, with -$291522.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 268.56% year-over-year to -$291522.0; the TTM figure through Mar 2026 stood at -$1.2 million (down 297.73% YoY), while the FY2025 annual figure was -$231386.0, down 448.15% from the prior year.
- Other Non Operating Income eased to -$291522.0 in Q1 2026 per NEUP's latest filing, from -$135659.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $629501.0 in Q4 2024 and bottomed at -$753796.0 in Q2 2025.
- Historically, Other Non Operating Income has averaged -$69319.5 across 4 years, with a median of -$61735.0 in 2025.
- On a YoY basis, Other Non Operating Income climbed as much as 273.17% in 2024 and fell as far as 17027.65% in 2024.
- Neuphoria Therapeutics' Other Non Operating Income stood at -$363508.0 in 2023, then soared by 273.17% to $629501.0 in 2024, then plunged by 121.55% to -$135659.0 in 2025, then slumped by 114.89% to -$291522.0 in 2026.
- Business Quant data shows NEUP's Other Non Operating Income at -$291522.0 in Q1 2026, -$135659.0 in Q4 2025, and -$61735.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -291,522.00 |
| Dec 31, 2025 | -135,659.00 |
| Sep 30, 2025 | -61,735.00 |
| Jun 30, 2025 | -753,796.00 |
| Mar 31, 2025 | 172,946.00 |
| Dec 31, 2024 | 629,501.00 |
| Sep 30, 2024 | -280,037.00 |
| Jun 30, 2024 | 106,084.00 |
| Mar 31, 2024 | 216,847.00 |
| Dec 31, 2023 | -363,508.00 |
| Sep 30, 2023 | -1,635.00 |